Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps. The Food and Drug Administration (FDA ...
– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...
Novartis and Roche have struggled to keep their aging asthma blockbuster Xolair relevant, especially as competition from rival drugs—like Sanofi and Regeneron's blockbuster Dupixent—mop up sales. But ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A medication used to treat asthma can now be ...
Roche announced that the US Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for Xolair (omalizumab) prefilled syringe for self-injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results